#None #Allergan #neurotoxin #Boey

Allergan Aesthetics Launches Boey® in Europe

Allergan Aesthetics, a subsidiary of AbbVie, has made headlines with the European Commission's approval of Boey® (trenibotulinumtoxinE), a pioneering treatment that stands as the first and only rapid-onset and short-duration neurotoxin approved for the temporary improvement of frown lines in adult patients. This marks a significant advancement in aesthetic medicine, offering adults a new solution for managing the visible signs of aging that may impact their psychological well-being.

Overview of Boey®

Boey® is specifically designed to improve the appearance of moderate to severe glabellar lines—commonly referred to as frown lines—between the eyebrows. With its innovative formulation, Boey® allows results to be seen as quickly as eight hours after treatment, making it unique among aesthetic injectables. Furthermore, the effects of this treatment are designed to last for approximately two to three weeks, providing a flexible option for those seeking aesthetic enhancements without long-term commitment.

This neurotoxin differs from others, as it concentrates on the exact area of concern, offering targeted relief and a natural appearance. The approval process for Boey® involved rigorous clinical testing, ensuring its efficacy and safety for patients looking for temporary solutions.

Clinical Trials and Efficacy

The approval of Boey® was supported by comprehensive phase 3 clinical trials involving 725 participants. These studies demonstrated a significant percentage of patients observing a marked improvement in their frown lines. The outcome measures utilized standardized assessments of wrinkle severity, confirming Boey®'s effectiveness in a wide range of individuals.

Furthermore, participants expressed a desire for treatment options that provide temporary results before committing to longer-lasting procedures—an insight that aligns perfectly with the benefits Boey® offers. With 80% of individuals open to exploring new treatments and 79% interested in previewing their results, this product meets an evident demand in the market.

The Future of Aesthetic Treatments

Allergan Aesthetics is actively preparing for the launch of Boey® across Europe. The company plans to support healthcare professionals through extensive education and training initiatives to ensure that Boey® is utilized effectively. This commitment to quality care goes beyond product release, with a focus on patient satisfaction and healthcare provider confidence in the new treatment.

Allergan's extensive portfolio in the aesthetics field—including its well-established BOTOX® Cosmetico—positions it as a leader in the injectable market. Boey®, developed from the same innovative principles, adds further strength to Allergan Aesthetics' offering, particularly as consumer interest in non-invasive treatments continues to rise.

Conclusion

The approval of Boey® marks a notable milestone not only for Allergan Aesthetics but also for the aesthetic industry at large. As adults become increasingly proactive about their appearance and the effects of aging, products like Boey® that promise quick results and minimal downtime will likely resonate in the marketplace. This innovative approach reflects a shift toward personalized aesthetic solutions that allow individuals to navigate their self-image on their terms.

For more information about Boey® and its upcoming launch, interested parties can visit Allergan Aesthetics.

In advancing the frontier of aesthetic treatments, Allergan continues to demonstrate its commitment to patients by delivering choice, comfort, and transformative solutions in the dynamic landscape of cosmetic care.